Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences, Inc. (NASDAQ: GILD) shares are trading higher on Wednesday, after a study of the company's remdesivir by the National Institute of Allergy and Infectious Diseases met its primary endpoint.

Why Gilead Stock Is Trading Higher Today

A phase 3 with the still-experimental antiviral treatment has met its primary endpoint.

Gilead Sciences Says Remdesivir Hit the Mark in COVID-19 Trial

Gilead's Coronavirus Drug Shows Positive Data

Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success

The market got a boost from news of a potential treatment for coronavirus.

Stocks Rally, Dow Up 400 Points After Gilead Treatment Shows ‘Positive Data’

The much-awaited results of U.S. trial of Gilead Sciences, Inc.'s (NASDAQ: GILD) investigational antiviral therapy remdesivir in treating coronavirus infection arrived Wednesday.

Gilead's Remdesivir Reaches Goal In NIAID-Sponsored Coronavirus Trial

Shares of GILD stock were halted early Wednesday after Gilead said a Phase 2 study of its coronavirus treatmnt had a positive result.
The post Gilead Reports Positive Result From Key Study Of Coronavirus Drug appeared first on Investor's Business Daily.

Gilead Reports Positive Result From Key Study Of Coronavirus Drug

Gilead Sciences Inc. GILD, +3.45% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 patients.

Gilead says shorter remdesivir regimen is effective and drug met main goal in government study

U.S. stock index futures jumped on Wednesday after Gilead Sciences  said its experimental antiviral drug met the main goal of a trial testing it in COVID-19 patients.

Futures jump after Gilead's COVID-19 drug meets main goal

Gilead Sciences Inc. GILD, -1.53% said Wednesday morning that a government-run clinical trial evaluating its experimental drug remdesivir in certain COVID-19 patients met the study's primary endpoint.

Gilead's stock halted, says remdesivir met primary endpoint in government study

GILD stock gets a lot of attention for its coronavirus therapy efforts, but the smart purchase of Gilead rests entirely on price action.
The post The Cure for Profitably in Buying Gilead Sciences appeared first on InvestorPlace.

The Cure for Profitably in Buying Gilead Sciences

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

Regeneron Pharmaceuticals

Vir Biotechnology

While the stock markets have declined this year due to the spread of the novel coronavirus, stocks of pharma companies developing treatments and vaccines for the highly contagious viral infection have fared quite well.

Best Coronavirus Treatment Stock: Gilead, Regeneron, Or Vir?

Alpha Pro Tech

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Rite Aid

Teladoc

Teva Pharmaceutical

Several healthcare stocks have jumped higher based off the coronavirus pandemic. But these nine companies have a longer upside pathway.

9 Healthcare Stocks to Buy Even After the Coronavirus Fades

Ampio Pharmaceuticals Inc

CytoDyn Inc.

Galectin Therapeutics

Roche Holding AG

Finding The Kink In COVID-19's Armor - Preventing ARDS

Biogen

These are the health care stocks with the best value, fastest growth, and most momentum for May.

Top Health Care Stocks for May 2020

Amgen

Incyte

Vertex Pharmaceuticals

Focus on Coronavirus Treatments to Boost Biotech Stocks

Late last week, a Financial Times report suggested that Gilead’s coronavirus candidate drug remdesivir was not effective. However, the narrative for GILD stock requires a much broader context.

Don’t Let Negative Data Dissuade You from Gilead Sciences

Synthetic antibodies and UV light could hold promise as a treatment for coronavirus.

Besides Remdesivir, These 2 COVID-19 Treatments Could Have Promise

Look for some lackluster financial results and potentially some heavily anticipated clinical results.

Here's What to Expect With Gilead Sciences' Q1 Earnings Update

Intel

Nordstrom

Morgan Stanley

Netflix

NVIDIA

Schlumberger

We take a look at winners and losers among last week's most talked about stocks.

Trending Stocks That Are Thriving While Others Are Crashing

Investors are waiting on pins and needles to see how the big biotech's experimental COVID-19 drug pans out.

Why Is the Stock Market Hanging Its Hopes on Gilead's Remdesivir?

The global economic slowdown hammered many of their peers, but swift decision-making has helped lift these two biotechs' shares much higher.

While Big Pharma Tanked, Gilead Sciences and Regeneron Soared

Adobe

Alibaba

Lockheed Martin

Microsoft

SPDR S&P 500 ETF Trust

Twilio

Are The Equity Markets Over Optimistic?

The company noted that the trial in question had ended early, and asserted that the data was being misinterpreted.

News for Gilead Sciences Stock (GILD)